SCOT: Tumor Sidedness and the Influence of Adjuvant Chemotherapy Duration on Disease Free Survival (DFS)
- 21 February 2023
- journal article
- research article
- Published by Elsevier in Clinical Colorectal Cancer
- Vol. 22 (2) , 231-237
Abstract
No abstract availableKeywords
Funding Information
- Medical Research Council (G0601705)
- Cancer Research UK (C6716/A13941)
- University of Glasgow (23516549)
This publication has 15 references indexed in Scilit:
- 3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): an international, randomised, phase 3, non-inferiority trialThe Lancet Oncology, 2018
- Duration of Adjuvant Chemotherapy for Stage III Colon CancerNew England Journal of Medicine, 2018
- Primary tumor sidedness has an impact on prognosis and treatment outcome in metastatic colorectal cancer: results from two randomized first-line panitumumab studiesAnnals of Oncology, 2017
- Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trialsAnnals of Oncology, 2017
- Sidedness is prognostic in locoregional colon cancer: an analysis of 9509 Australian patientsBMC Cancer, 2017
- Prognostic Survival Associated With Left-Sided vs Right-Sided Colon CancerJAMA Oncology, 2017
- The relevance of primary tumour location in patients with metastatic colorectal cancer: A meta-analysis of first-line clinical trialsEuropean Journal of Cancer, 2017
- The Worse Prognosis of Right-Sided Compared with Left-Sided Colon Cancers: a Systematic Review and Meta-analysisJournal of Gastrointestinal Surgery, 2016
- Does the primary site of colorectal cancer impact outcomes for patients with metastatic disease?Cancer, 2014
- Adjuvant Chemotherapy for Stage II Right-Sided and Left-Sided Colon Cancer: Analysis of SEER-Medicare DataAnnals of Surgical Oncology, 2014